Application of organic carbamates in drug design. Part 1: Anticancer agents - Recent reports

Drugs of the Future

Volumn 29, Issue 4, 2004, Pages 343-357

  Ray, Suprabhat ^a,b   Chatrurvedi, Devdutt ^a,c  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b Masonic Lodge Compound   (India)

^c UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,11A TETRAHYDRO 8 HYDROXY 7 METHOXY 5H PYRROLO[2,1 C][1,4]BENZODIAZEPIN 5 ONE; 2 BENZIMIDAZOLECARBAMIC ACID DERIVATIVE; ALKALOID DERIVATIVE; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBAMIC ACID DERIVATIVE; CARBAMIC ACID ESTER; CYTOTOXIC AGENT; DAUNORUBICIN; DAUNORUBICIN DERIVATIVE; DNA; DOCETAXEL; DOXORUBICIN; DSB 120; ETOPOSIDE; ETOPOSIDE DERIVATIVE; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GEIPARVARIN; IRINOTECAN; NATURAL PRODUCT; PACLITAXEL; PHENOL DERIVATIVE; PRODRUG; PYRIDO[3,4 B]PYRAZINE CARBAMATE; RHAZINILAM; SJG 136; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL CULTURE; CARDIOTOXICITY; CHEMICAL MODIFICATION; CHEMICAL REACTION; CLINICAL TRIAL; CONFORMATIONAL TRANSITION; CYTOPATHOGENIC EFFECT; DRUG CONFORMATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG MECHANISM; DRUG RELEASE; DRUG RESEARCH; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; IC 50; LUNG CANCER; MITOSIS INHIBITION; NONHUMAN; OVARY CANCER; REVIEW; STRUCTURE ANALYSIS; TECHNIQUE; TUMOR LOCALIZATION;

EID: 2642569934     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2004.029.04.787236     Document Type: Review

References (68)

1. Plimmer, J.R. Chemistry of pesticides. In: Handbook of Pesticide Toxicology, Vol. 1, Pesticide Risk Characterization. Academic Press 2002.
2. Ghosh, A.K. McKee, S.P., Thompson, W.J., Darke, P.L. Zugay, J.C. Potent HIV-1 protease inhibitors: Stereoselective synthesis of a dipeptide mimic. J Org Chem 1993, 58: 1025-9.
3. Green, T.W., Wuts, P.G.M. (Eds.). Protective Groups in Organic Synthesis, 3rd Ed. John Wiley and Sons: Newark 1999, 505-50.
4. Raju, B., Kassir, J.M., Kogan, T.P. Solution-phase combinatorial synthesis of ureas using nitrophenylcarbamates. Bioorg Med Chem Lett 1998, 8: 3043-8.
5. Hutchins, S.M., Chapman, K.T. A general method for the solid phase synthesis of ureas. Tetrahedron Lett 1994, 35: 4055-8.
6. Agourides, C., Denis, A., Auger, J.-M. et. al. Synthesis and anti-bacterial activity of ketolides (6-O-methyl-3-oxo-erythromycin derivatives): A new class of macrolide resistant and susceptible respiratory pathogens. J Med Chem 1998, 41: 4080-100.
7. 1 receptor agonist PD 170292. Bioorg Med Chem Lett 2000, 10: 1245-8.
8. Sharma, S., Abuzar, S. The benzimidazole anthelmintics - Chemistry and biological activity. In: Progress in Drug Research 27. Jucker, E. (Ed.). Birkhauser Verlag: Basel 1983.
9. Ingber, D., Fugita, T., Kishimoto, S., Sudo, K., Kanamann, T., Brem, H., Folkman, J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 1999, 348: 555-7.
10. AGM-1470. Drugs Fut 1994, 19: 981.
11. Dorey, G., Leon, P., Sciberras, S. et al. Synthesis and antiangiogenic activity of new carbohydrate derivatives. Bioorg Med Chem Lett 1996, 6: 3045-50.
12. Perron-Sierra, F.M., Pierré, A., Burbridge, M., Guilbaud, N. Novel bicyclic oxazolone derivatives as anti-angiogenic agents. Bioorg Med Chem Lett 2002, 12: 1463-6.
13. Baudoin, O., Cluvean, F., Thoret, S., Herrbach, A., Guenard, D., Cueritte F. Synthesis and biological evaluation of A-ring biaryl carbamate analogues of rhazinilam. Bioorg Med Res 2002, 10: 3395-400.
14. Temple, C. Jr., Rener, G.A. Antimitotic agents: Ring analogues and derivatives of ethyl [(S)-5-amino-1,2-djhydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-yl]carbamate. J Med Chem 1992, 35: 4809-12.
15. Temple, C. Jr., Rener, G.A. Antimitotic agents. Chiral isomers of ethyl [5-amino-1,2-dihydro-3-(4-hydroxyphenyl)-2-methylpyrido[3,4-b] pyrazin-7-yl] carbamate. J Med Chem 1992, 35: 988-93.
16. Temple, C. Jr., Rener, G.A., Comber, R.N. New anticancer agents: Alterations of the carbamate group of ethyl (5-amino- 1,2-dihydro-3-phenylpyrido[3,4-b]pyrazin-7-yl) carbamates. J Med Chem 1989, 32: 2363-7.
17. Temple, C. Jr., Rener, G.A. New anticancer agent chiral isomers of ethyl 5-amino-1,2-dehydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-yl-carbamate. J Med Chem 1989, 32: 2089-92.
18. Temple, C. Jr., Rener, G.A., Comber, R.N., Ward, W.R. Antimitotic agents. Alterations at the 2,3-positions of ethyl (4-amino-1,2-dehydro pyrido [3,4-b] pyrazine-7-yl) carbamates. J Med Chem 1991, 34: 3176-81.
19. Ram, S., Wise, A.S., Wotring, L.L., McCall, J.W., Townsend, L.B. Synthesis and biological activity of certain alkyl-5-(alkoxy-carbonyl)-1H-benzimidazole-2-carbamates and related derivatives. A new class of potential antineoplastic and antifilarial agents. J Med Chem 1992, 35: 539-47.
20. Kumar, Y., Green, R., Borysko, K.Z., Wise, D.S., Wotring, L.L., Townsend, L.B. Synthesis of 2,4-disubstituted triazoles as potential antitumour and antifilarial agents. I: Methyl 4-(isothiocyanatomethyl) tetrazole-2-carbamates, -selenazole-2-carbamates, and related derivatives. J Med Chem 1999, 36: 3843-8.
21. Wani, M.C., Taylor, H.L., Wall, M.E., Coggon, P., McPhail, A.T. Plant antitumor agent VI. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia J Am Chem Soc 1971, 93: 2325-7.
22. Gueritte-Voegelein, F., Guenard, D., Lavelle, F., LeGoff, M.T., Mangatal, L., Potier, P. Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem 1991, 34: 992-8.
23. Ringel, I., Horwitz, S.B. Studies with RP 56976 (Taxotere): A semisynthetic analog of Taxol. J Natl Cancer Inst 1991, 83: 288-91.
24. Bissery, M.C., Guenard, D., Gueritte-Voegelein, F., Lavelle, F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 1991, 51: 4845-52.
25. Ali, S.M., Hoemann, M.Z., Aube, J., Mitscher, L.A., Georg, G.I., McCall, R., Jayasinghe L.R. Novel cytotoxic 3′-(tert butyl) 3′-dephenyl analogs of paclitaxel and docetaxel J Med Chem 1995, 38: 3821-8.
26. Fang, W.S., Liu, Y., Liu, H.-Y., Xu, S.-F., Wang, L., Fang, Q.-C. Synthesis and cytotoxicity of 2-amido docetaxel analogues. Bioorg Med Chem Lett 2002, 12: 1543-6.
27. Zhu, J.W., Hori, H., Jajiri, H., Tsukuda, T., Taira, Z. Synthesis and activity of brefeldin A analogs as inducers of cancer cell differentiation and apoptosis. Bioorg Med Chem Lett 1997, 7: 139-44.
28. Ojima, I., Slater, J.C., Michand, E. et al. Synthesis and structure activity relationship of the second generation antitumor taxoids: Exceptional activity against drug-resistant cancer cells. J Med Chem 1996, 39: 3889-96.
29. deGroot, F.M.H., Van Berkom, L.W.A., Scheeren, H.W. Synthesis and biological evaluation of 2′-carbamate-linked and 2′ -carbonate-linked prodrugs of paclitaxel: Selective activation by the tumor-associated protease plasmin. J Med Chem 2000, 43: 3093-102.
30. Lakey, F.N., McLeod, J.E. The coumarins of Geijera parviflora Lindl. Anst J Chem 1967, 20: 1943-67.
31. Simoni, D., Manfredini, S., Tabrizi, M.A., Bazanini, R. Baraldi, P.G., Baljarini, J., Clereq, E.D. Geiparvarin analogues 2. Synthesis and cytostatic activity of 5-(4-arylbutadienyl)-3 (2H)-furanones and N-substituted 3-(4-oxo-2-furanyl)-2-buten-2-yl carbamates. J Med Chem 1991, 34: 3172-6.
32. Brown, J.R. Adriamycin and related anthracycline antibiotics. Prog Med Chem 1978, 15: 125.
33. Adams, N., Blake, C., Broadhurst, M.J. et al. Synthesis and antitumor activity of 9-[(carbamoyloxy)alkyl] anthracyclines. A novel class of anthracycline derivatives. J Med Chem 1990, 33: 2380-4.
34. Maligres, P.E., Nicolaou, K.C., Wrasidlo, W. A new designed tumor selective daunomycin derivative. Bioorg Med Chem Lett 1993, 3: 1051-4.
35. Hamilton, T.C., Winker, M.A., Louie, K.G. et al. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and sensitive human ovarian carcinoma cell lines by buthionine sulfoxime mediated glutathione depletion. Biochem Pharmacol 1985, 34: 2583-6.
36. Izawa, T., Kato, K. Design and synthesis of an antitumor prodrug released by the reaction with sulfhydryl compounds. Bioorg Med Chem Lett 1995, 5: 593-6.
37. Florent, J.-C., Dong, X., Gandel, G. et al. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy. J Med Chem 1998, 41: 3572-81.
38. Connors, T.A. Antitumor drug with latent activity. Biochemistry 1978, 60: 979-87.
39. Bagshawe, K.D., Springer, C.J., Searle, F. et al. A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer 1988, 58: 700-3.
40. Senter, P.D., Saulnier, M.G., Schreiber, G.J., Hirschberg, D.L., Brown, J.P., Hellstrom, I., Hellstrom, K.E. Antitumor effect of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci USA 1988, 85: 4842-62.
41. Shabat, D., Lode, H.N., Pertl, U., Reisfeld, R.A., Rader, C., Lerner, R.A., Barbas, C.F. In vivo activity in catalytic antibody prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapy. Proc Natl Acad Sci USA 2001, 98: 7528-33.
42. Schmidt, F., Monneret C. Prodrug monotherapy: Synthesis and biological evaluation of an etoposide glucuronide-prodrug. Bioorg Med Chem 2003, 11: 2277-83.
43. Wall, M.E., Wani, M.C., Cook, C.E., Palmer, K.H., McPhail, A.T., Sim, G.A. Plant-antitumor agents I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Acuminata. J Am Chem Soc 1966, 88: 3888-90.
44. Kingsbury, W.D., Boehm, J.C., Jakes, D.R. et al. Synthesis of water soluble (aminoalkyl) camptothecin analogues: Inhibition of topoisomerase I and antitumor activity. J Med Chem 1991, 34: 98-107.
45. Luzzio, M.J., Besterman, J.M., Emerson, D.L. et al. Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I. J Med Chem 1995, 38: 395-401.
46. Angenault, S., Thirot, S., Schmidt, F., Monneret, C., Pfeiffer, B., Renard, P. Cancer chemotherapy. A SN 38 (7-ethyl-10-hydroxycamptothecin) glucuronide prodrug for treatment by a PMT (prodrug monotherapy) strategy. Bioorg Med Chem Lett 2003, 13: 947-50.
47. Leu, Y.-L., Roffler, S.R., Chern, J.-W. Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody directed enzyme prodrug therapy. J Med Chem 1999, 42: 3623-8.
48. a) Nicolaou, K.C., Dai, W.M., Tsay, S.C., Esterez, V.A., Wrasidlo, W. Designed enediynes. A new class of DNA clearing molecules with potent and selective anticancer activity. Science 1992, 256: 1172-8;
49. b) Unno, R., Michishita, H., Inagaki, H. et al. Structure-activity relationship of cyclic enediynes related to dynemicin A-I. Synthesis and antitumor activity of 9-acetoxy enediynes equipped with aryl carbamate moieties. Bioorg Med Chem 1997, 5: 883-901;
50. c) Unno, R., Michishita, H., Inagaki, H. et al. Structure-activity relationship of cyclic enediynes related to dynemicin A-II. Synthesis and antitumor activity of 9- and 12-substituted enediynes equipped with aryl carbamate moieties. Bioorg Med Chem 1997, 5: 903-19;
51. d) Unno, R., Michishita, H., Inagaki, H. et al. Synthesis and antitumor activity of water soluble enediyne compounds related to dynemicin A. Bioorg Med Chem 1997, 5: 987-99.
52. a) Hay, M.P., Wilson, W.R., Denny, W.A. A novel enediyne prodrug for antibody directed enzyme prodrug therapy (ADEPT) using E. coli B nitroreductase. Bioorg Med Chem Lett 1995, 5: 2829-34;
53. b) Hay, M.P., Wilson, W.R., Denny, W.A. Nitrobenzyl carbamate prodrugs of enediynes for nitroreductase gene-directed enzyme prodrug therapy (GDEPT). Bioorg Med Chem Lett 1999, 9: 3417-22.
54. Wender, P.A., Zercher, C.K., Beckham, S., Houbold, E.M. A photochemically triggered DNA cleaving agent: Synthesis, mechanistic and DNA cleavage studies on a new analog of the antitumor antibiotic dynemicin. J Org Chem 1993, 58: 5867-72.
55. Wender, P.A., Beckham, S., O'Leary, J.G. A second generation photochemically activatable dynemicin analog: A concise synthesis and DNA cleavage studies. Synthesis 1994, 1278-82.
56. Dowell, R.I., Springer, C.J., Davies, D.H. et al. New mustard prodrugs of antibody directed enzyme prodrug therapy: Alternative to the amide link. J Med Chem 1996, 39: 1100-5.
57. Schmidt, F., Florent, J.C., Monneret, C., Straub, R., Czech, J., Gerken, M., Bosslat, K. Glucuronide prodrugs of hydroxy compounds for antibody directed enzyme prodrug therapy: A phenyl nitrogen mustard carbamate. Bioorg Med Chem Lett 1997, 1: 1071-6.
58. Papot, S., Comband, D., Bosslet, K., Gerken, M., Czech, J., Gesson, J.-P. Synthesis and cytotoxic activity of a glucuronylated prodrug of nor nitrogen mustard. Bioorg Med Chem Lett 2000, 10: 1835-7.
59. Hay, M.P., Wilson, W.R., Denny, W.A. Design synthesis and evaluation of imidazolyl methyl carbonate prodrugs of alkylating agents. Tetrahedron 2000, 56: 645-57.
60. Jordan, A.M., Khan, T.H., Osborn, H.M.I., Photion, A., Riley, P.A. Melanocyte-directed enzymes prodrug therapy (MDEPT): Development of a targeted treatment for malignant melanoma. Bioorg Med Chem 1999, 1: 1775-80.
61. Reynold, R.C., Tiwari, A., Harwell, J.E. et al. Synthesis and evaluation of several new (2-chloroethyl) nitrosocarbamates as potential anticancer agents. J Med Chem 2000, 43: 1484-8.
62. Sagnon, M.J., Howard, P.W., Gregson, S.J., Eno-Amooquayl, E., Burke, P.J., Thurston, D.E. Design and synthesis of novel pyrrolobenzodiazepine (PBD) prodrugs for ADEPT and GDEPT. Bioorg Med Chem Lett 2000, 10: 2083-6.
63. Elliot, W.L., Fry, D.W., Anderson, W.K., Nelson, J.M., Hook, K.E., Howkins, P.A., Leopold, W.R. In vivo and in vitro evaluation of the alkylating agent carmethizole. Cancer Res 1991, 51: 4581-7.
64. Atwell, G.J., Fan, J.-Y., Tan, K., Denny, W.A. DNA directed alkylating agents 7. Synthesis, DNA interaction and antitumor activity of bis (hydroxymethyl) and bis(carbamate)-substituted pyrrolizines and imidazoles. J Med Chem 1998, 41: 4744-54.
65. Atwell, G.J., Tercel, M., Boyd, M., Wilson, W.R., Denny, W.A. Synthesis and cytotoxicity of 5-amino-1-(chloromethyl)-3-[5,6,7-(trimethoxy indole-2-yl)carbonyl]-1,2-dihydro-3H-benz[e]indole (amino-seco-CBI-TMI) and related 5-alkylamino analogues: New DNA minor groove alkylating agents. J Org Chem 1998, 63: 9414-20.
66. Hay, M.P., Sykes, B.M., Denny, W.A., Wilson, W.R. A 2-nitroimidazole carbamate prodrug of 5-amino-1-(chloromethyl)-3-[(5,6, 7-trimethoxyindol-2-yl)carbonyl]-1,2-dihydro-3H-benz[e] indole (amino-seco-CBI-TMI) for use with ADEPT and GDEPT Bioorg Med Chem Lett 1999, 9: 2237-42.
67. 2 inhibition of nitroreductase. Biochem Biophys Res Commun 1975, 67: 1267-74.
68. Greenwald, R.B., Pendri, A., Conover, C.D. et al. Drug delivery systems employing 1,4- or 1,6-elimination: Poly(ethylene glycol) prodrugs of amine containing compounds. J Med Chem 1999, 42: 3657-67.